The South and Central America transient protein expression market is projected to reach US$ 56.1 million by 2027 from US$ 40.3 million in 2019; it is expected to grow at a CAGR of 4.4% during 2020–2027.
The market growth in this region is primarily attributed to factors such as the increasing applications of protein expression and growing adoption of precision medicines. However, the high cost of products limits the transient protein expression market growth.
Pharmaceutical and biotechnology industries have developed various techniques to treat cancer and neurodegenerative diseases. Transient gene expression technique has led to significant developments in the research related to neurotrauma and neurodegenerative and resulted in the introduction of precision medicines for these conditions. Technological advancements in epigenetics, genetics, and proteomics are supporting the development of therapeutics for the treatment of various genetic and rare genetic diseases caused by single and multiple cell disorders. Thus, the continuous research and development activities, and growing government initiatives to support precision medicine boost the adoption of transient protein expression techniques.
However, demand for transient protein expression systems in this pandemic is inclined from the outbreak of Covid-19, but now the pharma companies are working on developing strategies to develop and manufacture the required reagents, instruments for the research of vaccine fulfill the demands of transient protein expression. The demand of transient protein expression in the region is expected to increase due to the rising Covid-19 cases and other diseases such as cancer. The impact of the COVID19 pandemic on the regional transient protein expression market is moderate.
Based on product type, the South and Central America transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held the largest market share in 2019, whereas the expression vectors segment is anticipated to register the highest CAGR during the forecast period.
Based on application, the South and Central America transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held the largest market share in 2019, and it is expected to register the highest CAGR in the market during 2020–2027.
The South and Central America transient protein expression market, by end user, is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held the largest market share in 2019; it is estimated to register the highest CAGR in the market from 2020 to 2027.
“Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing,” (2019) and Thermo Fisher Scientific Inc., are among the key sources associated with the South and Central America transient protein expression market report.
Reasons to Buy
Pharmaceutical and biotechnology industries have developed various techniques to treat cancer and neurodegenerative diseases. Transient gene expression technique has led to significant developments in the research related to neurotrauma and neurodegenerative and resulted in the introduction of precision medicines for these conditions. Technological advancements in epigenetics, genetics, and proteomics are supporting the development of therapeutics for the treatment of various genetic and rare genetic diseases caused by single and multiple cell disorders. Thus, the continuous research and development activities, and growing government initiatives to support precision medicine boost the adoption of transient protein expression techniques.
However, demand for transient protein expression systems in this pandemic is inclined from the outbreak of Covid-19, but now the pharma companies are working on developing strategies to develop and manufacture the required reagents, instruments for the research of vaccine fulfill the demands of transient protein expression. The demand of transient protein expression in the region is expected to increase due to the rising Covid-19 cases and other diseases such as cancer. The impact of the COVID19 pandemic on the regional transient protein expression market is moderate.
Based on product type, the South and Central America transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held the largest market share in 2019, whereas the expression vectors segment is anticipated to register the highest CAGR during the forecast period.
Based on application, the South and Central America transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held the largest market share in 2019, and it is expected to register the highest CAGR in the market during 2020–2027.
The South and Central America transient protein expression market, by end user, is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held the largest market share in 2019; it is estimated to register the highest CAGR in the market from 2020 to 2027.
“Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing,” (2019) and Thermo Fisher Scientific Inc., are among the key sources associated with the South and Central America transient protein expression market report.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South and Central America transient protein expression market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South and Central America transient protein expression market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth, offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. South and Central America Transient Protein Expression Market - Market Landscape
5. South and Central America Transient Protein Expression Market - Key Market Dynamics
6. Transient Protein Expression Market - South and Central America Analysis
7. South and Central America Transient Protein Expression Market Analysis and Forecasts To 2027 - By Product Type
8. South and Central America Transient Protein Expression Market Analysis and Forecasts to 2027- By Application
9. South and Central America Transient Protein Expression Market Analysis and Forecasts to 2027- By End User
10. Transient Protein Expression Market Revenue and Forecasts to 2027 - Geographical Analysis
11. Impact Of COVID-19 Pandemic on South and Central America Transient Protein Expression Market
12. Industry Landscape
13. COMPANY PROFILES
14. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Thermo Fisher Scientific Inc.
- MERCK KGaA
- QIAGEN
- GenScript
- Promega Corporation
- Takara Bio Inc.
- MERIDIAN BIOSCIENCE, INC.
- New England Biolabs
- Mirus Bio LLC
- Agilent Technologies, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| Published | May 2021 |
| Forecast Period | 2019 - 2027 |
| Estimated Market Value ( USD | $ 40.3 Million |
| Forecasted Market Value ( USD | $ 56.1 Million |
| Compound Annual Growth Rate | 4.4% |
